Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)
Mouhamad Nasser
(1, 2)
,
Sophie Larrieu
(3)
,
Loic Boussel
(2, 4, 5)
,
Salim Si-Mohamed
(4)
,
Fabienne Bazin
(3)
,
Sébastien Marque
(3)
,
Jacques Massol
,
Françoise Thivolet-Bejui
(2)
,
Lara Chalabreysse
(2)
,
Delphine Maucort-Boulch
(6, 2, 7)
,
Eric Hachulla
(8, 9)
,
Stéphane Jouneau
(10, 11)
,
Katell Le Lay
,
Vincent Cottin
(1, 2)
1
IVPC -
Infections Virales et Pathologie Comparée - UMR 754
2 HCL - Hospices Civils de Lyon
3 IQVIA
4 CREATIS - Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé
5 MYRIAD - Modeling & analysis for medical imaging and Diagnosis
6 LBBE - Laboratoire de Biométrie et Biologie Evolutive - UMR 5558
7 Service de Biostatistiques [Lyon]
8 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
9 INFINITE (Ex-Liric) - Institute for Translational Research in Inflammation - U 1286
10 EHESP - École des Hautes Études en Santé Publique [EHESP]
11 Irset - Institut de recherche en santé, environnement et travail
2 HCL - Hospices Civils de Lyon
3 IQVIA
4 CREATIS - Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé
5 MYRIAD - Modeling & analysis for medical imaging and Diagnosis
6 LBBE - Laboratoire de Biométrie et Biologie Evolutive - UMR 5558
7 Service de Biostatistiques [Lyon]
8 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
9 INFINITE (Ex-Liric) - Institute for Translational Research in Inflammation - U 1286
10 EHESP - École des Hautes Études en Santé Publique [EHESP]
11 Irset - Institut de recherche en santé, environnement et travail
Mouhamad Nasser
- Fonction : Auteur
- PersonId : 784014
- ORCID : 0000-0001-8373-8032
Loic Boussel
- Fonction : Auteur
- PersonId : 19917
- IdHAL : loic-boussel
- ORCID : 0000-0001-9053-8127
Salim Si-Mohamed
- Fonction : Auteur
- PersonId : 791090
- ORCID : 0000-0003-0314-4010
Jacques Massol
- Fonction : Auteur
Lara Chalabreysse
- Fonction : Auteur
- PersonId : 759097
- ORCID : 0000-0002-4191-6547
Delphine Maucort-Boulch
- Fonction : Auteur
- PersonId : 1267466
- IdHAL : delphine-maucort-boulch
- ORCID : 0000-0003-0042-7787
- IdRef : 094595771
Eric Hachulla
- Fonction : Auteur
- PersonId : 1366882
- ORCID : 0000-0001-7432-847X
- IdRef : 031788866
Stéphane Jouneau
- Fonction : Auteur
- PersonId : 760799
- ORCID : 0000-0002-1949-3461
- IdRef : 124283659
Katell Le Lay
- Fonction : Auteur
Vincent Cottin
- Fonction : Auteur correspondant
- PersonId : 784269
- ORCID : 0000-0002-5591-0955
- IdRef : 166774731
Résumé
BACKGROUND: There is a paucity of data on the epidemiology, survival estimates and healthcare resource utilisation and associated costs of patients with progressive fibrosing interstitial lung disease (PF-ILD) in France. An algorithm for extracting claims data was developed to indirectly identify and describe patients with PF-ILD in the French national administrative healthcare database.METHODS: The French healthcare database, the Système National des Données de Santé (SNDS), includes data related to ambulatory care, hospitalisations and death for 98.8% of the population. In this study, algorithms based on age, diagnosis and healthcare consumption were created to identify adult patients with PF-ILD other than idiopathic pulmonary fibrosis between 2010 and 2017. Incidence, prevalence, survival estimates, clinical features and healthcare resource usage and costs were described among patients with PF-ILD.RESULTS: We identified a total of 14,413 patients with PF-ILD. Almost half of them (48.1%) were female and the mean (± standard deviation) age was 68.4 (± 15.0) years. Between 2010 and 2017, the estimated incidence of PF-ILD ranged from 4.0 to 4.7/100,000 person-years and the estimated prevalence from 6.6 to 19.4/100,000 persons. The main diagnostic categories represented were exposure-related ILD other than hypersensitivity pneumonitis (n = 3486; 24.2%), idiopathic interstitial pneumonia (n = 3113; 21.6%) and rheumatoid arthritis-associated ILD (n = 2521; 17.5%). Median overall survival using Kaplan-Meier estimation was 3.7 years from the start of progression. During the study, 95.2% of patients had ≥ 1 hospitalisation for respiratory care and 34.3% were hospitalised in an intensive care unit. The median (interquartile range) total specific cost per patient during the follow-up period was €25,613 (10,622-54,287) and the median annual cost per patient was €18,362 (6856-52,026), of which €11,784 (3003-42,097) was related to hospitalisations. Limitations included the retrospective design and identification of cases through an algorithm in the absence of chest high-resolution computed tomography scans and pulmonary function tests.CONCLUSIONS: This large, real-world, longitudinal study provides important insights into the characteristics, epidemiology and healthcare resource utilisation and costs associated with PF-ILD in France using a comprehensive and exhaustive database, and provides vital evidence that PF-ILD represents a high burden on both patients and healthcare services. Trial registration ClinicalTrials.gov, NCT03858842. ISRCTN, ISRCTN12345678. Registered 3 January 2019-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03858842.
Format du dépôt | Fichier |
---|---|
Type de dépôt | Article dans une revue |
Résumé |
en
BACKGROUND: There is a paucity of data on the epidemiology, survival estimates and healthcare resource utilisation and associated costs of patients with progressive fibrosing interstitial lung disease (PF-ILD) in France. An algorithm for extracting claims data was developed to indirectly identify and describe patients with PF-ILD in the French national administrative healthcare database.METHODS: The French healthcare database, the Système National des Données de Santé (SNDS), includes data related to ambulatory care, hospitalisations and death for 98.8% of the population. In this study, algorithms based on age, diagnosis and healthcare consumption were created to identify adult patients with PF-ILD other than idiopathic pulmonary fibrosis between 2010 and 2017. Incidence, prevalence, survival estimates, clinical features and healthcare resource usage and costs were described among patients with PF-ILD.RESULTS: We identified a total of 14,413 patients with PF-ILD. Almost half of them (48.1%) were female and the mean (± standard deviation) age was 68.4 (± 15.0) years. Between 2010 and 2017, the estimated incidence of PF-ILD ranged from 4.0 to 4.7/100,000 person-years and the estimated prevalence from 6.6 to 19.4/100,000 persons. The main diagnostic categories represented were exposure-related ILD other than hypersensitivity pneumonitis (n = 3486; 24.2%), idiopathic interstitial pneumonia (n = 3113; 21.6%) and rheumatoid arthritis-associated ILD (n = 2521; 17.5%). Median overall survival using Kaplan-Meier estimation was 3.7 years from the start of progression. During the study, 95.2% of patients had ≥ 1 hospitalisation for respiratory care and 34.3% were hospitalised in an intensive care unit. The median (interquartile range) total specific cost per patient during the follow-up period was €25,613 (10,622-54,287) and the median annual cost per patient was €18,362 (6856-52,026), of which €11,784 (3003-42,097) was related to hospitalisations. Limitations included the retrospective design and identification of cases through an algorithm in the absence of chest high-resolution computed tomography scans and pulmonary function tests.CONCLUSIONS: This large, real-world, longitudinal study provides important insights into the characteristics, epidemiology and healthcare resource utilisation and costs associated with PF-ILD in France using a comprehensive and exhaustive database, and provides vital evidence that PF-ILD represents a high burden on both patients and healthcare services. Trial registration ClinicalTrials.gov, NCT03858842. ISRCTN, ISRCTN12345678. Registered 3 January 2019-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03858842.
|
Titre |
en
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)
|
Auteur(s) |
Mouhamad Nasser
1, 2
, Sophie Larrieu
3
, Loic Boussel
2, 4, 5
, Salim Si-Mohamed
4
, Fabienne Bazin
3
, Sébastien Marque
3
, Jacques Massol
, Françoise Thivolet-Bejui
2
, Lara Chalabreysse
2
, Delphine Maucort-Boulch
6, 2, 7
, Eric Hachulla
8, 9
, Stéphane Jouneau
10, 11
, Katell Le Lay
, Vincent Cottin
1, 2
1
IVPC -
Infections Virales et Pathologie Comparée - UMR 754
( 1002418 )
- 50 Avenue Tony Garnier
69366 Lyon Cedex 07
- France
2
HCL -
Hospices Civils de Lyon
( 300074 )
- 3 Quai des Célestins
69002 Lyon
- France
3
IQVIA
( 533761 )
- France
4
CREATIS -
Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé
( 139739 )
- 7 avenue Jean Capelle, Bat Blaise Pascal, 69621 Villeurbanne Cedex
- France
5
MYRIAD -
Modeling & analysis for medical imaging and Diagnosis
( 1043804 )
- France
6
LBBE -
Laboratoire de Biométrie et Biologie Evolutive - UMR 5558
( 10025 )
- 43 Bld du 11 Novembre 1918 69622 VILLEURBANNE CEDEX
- France
7
Service de Biostatistiques [Lyon]
( 82539 )
- Lyon
- France
8
CHRU Lille -
Centre Hospitalier Régional Universitaire [CHU Lille]
( 425779 )
- CHU/CHRU Lille - 2, avenue Oscar Lambret - 59037 Lille Cedex
- France
9
INFINITE (Ex-Liric) -
Institute for Translational Research in Inflammation - U 1286
( 1031145 )
- Faculté de Médecine - Pôle Recherche, 4ème étage - 1 place de Verdun - 59045 LILLE CEDEX
- France
10
EHESP -
École des Hautes Études en Santé Publique [EHESP]
( 301986 )
- 15, avenue du Pr. Léon Bernard - 35043 Rennes Cedex
- France
11
Irset -
Institut de recherche en santé, environnement et travail
( 182194 )
- 263 avenue Général Leclerc 35042 Rennes Cedex
- France
|
Nom de la revue |
|
Date de publication |
2021-12
|
Date de publication électronique |
2021-05-24
|
Public visé |
Scientifique
|
Sous-type de document pour les Articles |
Research article
|
Licence |
Paternité
|
Langue du document |
Anglais
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Volume |
22
|
Numéro |
1
|
Page/Identifiant |
162
|
Domaine(s) |
|
Mots-clés (JEL) |
|
Financement |
|
Mots-clés |
en
Algorithms, Epidemiology, Healthcare resource utilisation, Interstitial lung disease, Progressive fibrosis
|
DOI | 10.1186/s12931-021-01749-1 |
Pubmed Id | 34030695 |
UT key WOS | 000657781700003 |
Origine :
Fichiers éditeurs autorisés sur une archive ouverte
Loading...